ABBVIE
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 443
- Registration Number
- NCT02993523
- Locations
- 🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 162534, Atlanta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 201133, Chicago, Illinois, United States
🇺🇸University of Chicago Medicine /ID# 154108, Chicago, Illinois, United States
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT02988960
- Locations
- 🇨🇦
University Health Network_Princess Margaret Cancer Centre /ID# 200819, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 156324, Los Angeles, California, United States
🇺🇸The University of Chicago Medical Center /ID# 155264, Chicago, Illinois, United States
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
- Conditions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 139
- Registration Number
- NCT02988674
- Locations
- 🇷🇺
Institution KhMAO-Ugra /ID# 154381, Khanty-mansiysk, Russian Federation
🇷🇺State Clinical Hospital /ID# 154373, Moscow, Russian Federation
🇷🇺Research Institute of Rheum /ID# 154378, Moscow, Russian Federation
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 145
- Registration Number
- NCT02986373
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 378
- Registration Number
- NCT02985879
- Locations
- 🇺🇸
Usc /Id# 149773, Los Angeles, California, United States
🇺🇸Mayo Clinic - Scottsdale /ID# 144893, Scottsdale, Arizona, United States
🇺🇸Ucsd /Id# 144905, La Jolla, California, United States
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 210
- Registration Number
- NCT02980731
- Locations
- 🇦🇺
St George Hospital /ID# 154212, Kogarah, New South Wales, Australia
🇦🇺Liverpool Hospital /ID# 154950, Liverpool, New South Wales, Australia
🇦🇺Gold coast University Hospital /ID# 150833, SouthPort, Queensland, Australia
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 50
- Registration Number
- NCT02968173
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT02966756
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital /ID# 209458, Hefei, Anhui, China
🇨🇳The Second Hospital of Hebei Medical University /ID# 159143, Shijiazhuang, Hebei, China
🇨🇳West China Hospital, Sichuan University /ID# 156537, Chengdu, Sichuan, China
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 84
- Registration Number
- NCT02966795
- Locations
- 🇧🇪
AZ Groeninge /ID# 157029, Kortrijk, Belgium
🇫🇷Hopital Haut-Lévêque /ID# 157035, Pessac CEDEX, Gironde, France
🇦🇺Nepean Hospital Kingswood /ID# 157027, Kingswood, New South Wales, Australia
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT02966782
- Locations
- 🇺🇸
Duplicate_University of Chicago /ID# 155364, Chicago, Illinois, United States
🇺🇸University of Massachusetts - Worcester /ID# 155366, Worcester, Massachusetts, United States
🇦🇺Royal Perth Hospital /ID# 155951, Perth, Western Australia, Australia